Cabbacis is the global leader in developing consumer products with blends of reduced-nicotine tobacco and hemp. The Company’s worldwide patent portfolio consists of 35 issued product patents and various pending patent applications across the world. Learn more about our company, products and licensing opportunities.
The demand for products to help cigarette smokers smoke less, quit altogether, or switch to less harmful products continues to increase—that’s where Cabbacis comes in. As a federally-licensed tobacco product manufacturer, our primary products in development include patented reduced-nicotine cigarettes and vaporizer pods to assist smokers to smoke less or switch to less harmful products.
Almost half of the 28 million adult cigarette smokers in the US attempt to quit each year, but only about five percent are permanently successful. Cabbacis products aim to reduce the harm from smoking with patented reduced-nicotine cigarettes and vaporizer pods (both comprising blends of very-low-nicotine tobacco and hemp) to assist smokers of conventional cigarettes to smoke less or switch to less harmful products. Another potential application is to assist co-users of tobacco smoking/vaping and marijuana (high THC) smoking/vaping who require treatment for marijuana use disorder.
Benefitting public health is a driving impetus for Cabbacis products, created with a focus to assist smokers in smoking less or transitioning to less harmful products. Smoking reduced-nicotine cigarettes or switching, for example, to e-cigarettes will become a necessity upon the implementation of the FDA’s new product standard of limiting nicotine content for all combustible cigarettes, as announced by the FDA on June 21, 2022. The FDA reiterated these plans various times, including in a January 15, 2025 press release, in which the FDA issued a proposed rule that, if finalized, would make cigarettes minimally or nonaddictive by limiting the level of nicotine (~ 95% reduced). Upon FDA implementation of this product standard, our reduced-nicotine cigarettes with FDA authorization would be relevant and differentiated among the other reduced-nicotine cigarettes sold in the US.
Dozens of independent, peer-reviewed, research studies and clinical trials have demonstrated the efficacy of reduced-nicotine cigarettes as a useful tool in smoking less and reducing nicotine consumption. For example, see this study published in the New England Journal of Medicine and this study published in the Journal of the American Medical Association (JAMA). With hemp as an additional component in the filler of Cabbacis reduced-nicotine cigarettes, the company believes effectiveness including clinical trial outcomes will improve, as compared to reduced-nicotine cigarettes without hemp. Hemp contains very low THC levels and does not cause intoxication, and in some strains THC is non-detectable. Moreover, the presence of hemp is expected to also improve overall product acceptability.
Our extensive international patent portfolio includes two significant patent families, 35 issued patents, and many pending patent applications across the globe. If you’re looking for tobacco or cannabis investment opportunities, we’d like to speak with you.
View Our IP
We’re here to answer any questions and provide additional information about our company, products, research and development, and information on potential collaborations, investments or licensing. Fill out the form below or email support@cabbacis.com.